1. Introduction {#s0005}
===============

The recently proposed research diagnosis of preclinical Alzheimer\'s disease is primarily based on brain abnormalities detected by amyloid PET, FDG-PET, or volumetric MRI in elderly HC subjects ([@bb0165]). From a clinical point of view, a crucial question is the accuracy of such neuroimaging measures for the prediction of clinical progression to AD dementia in HC subjects. Previous studies showed that medial temporal lobe FDG-PET hypometabolism was associated with subsequent conversion to MCI or AD dementia ([@bb0045; @bb0110]). However, the accuracy of medial temporal lobe FDG-PET remained below a clinically significant level for the prediction of progression to MCI ([@bb0110]). Results from studies assessing volumetric MRI in elderly HC subjects suggested that regional GM volume decrease was associated with increased risk to develop AD dementia ([@bb0050; @bb0060]). However, the accuracy of FDG-PET and GM volume for predicting AD dementia in HC is still unclear, and to our best knowledge, no studies have compared the utility of FDG-PET and MRI for the detection of preclinical AD so far. Importantly, although slight cognitive changes have been proposed to be part of the preclinical stage of AD ([@bb0165]), the diagnostic benefit of combining neuropsychological test and neuroimaging modalities has not been tested.

Therefore, the major aim of the current study was to assess the predictive accuracy of regional FDG-PET metabolism, MRI assessed gray matter volume and neuropsychological test performance for predicting clinical progression to MCI or AD dementia in elderly HC subjects. For neuropsychological test scores, we used tests of free recall and the trail making test B (TMT-B) --- a measure of executive function --- since these tests were previously shown to be predictive of the clinical progression from MCI to AD dementia ([@bb0075]).

2. Data and methods {#s0020}
===================

2.1. Subjects {#s0025}
-------------

All subjects were recruited within the multicenter Alzheimer\'s Disease Neuroimaging Initiative (ADNI, <http://www.adni-info.org/>) and all data and scans were obtained from ADNI\'s publicly available databank (<http://adni.loni.ucla.edu/>). In ADNI, the general inclusion criteria were an age between 55 and 90 years, a modified Hachinski score ≤ 4, education of at least 6 grade level, and stable treatment of at least 4 weeks in case of treatment with permitted medication (for full list see <http://www.adni-info.org>, Procedures Manual).

A total of 54 HC subjects were included for testing the prediction of the development of MCI or AD dementia. To be included in the current study, HC subjects had to have 1) HC diagnosis at baseline, 2) baseline MRI and FDG-PET scan, 3) conversion to MCI or AD during clinical follow-up or a clinical follow-up interval of at least 36 months, and 4) a clinical dementia rating (CDR) score = 0 at each follow-up time point in HC non-converters (see for flow chart [Fig. 1](#f0005){ref-type="fig"}). The CDR requirement in the HC non-converters was done in order to have a clean control group to be contrasted against HC subjects who show clinical progression. Such a study design was considered useful to boost power for establishing a prediction model that clearly distinguishes between HC converters and those HC subjects who remain stable. The requirement of at least 36 months of follow-up time for all HC subjects was implemented in order to reduce censoring effects.

The ROIs of FDG-PET and GM volume as predictors of clinical progression were *a priori* established in a training sample including 78 amnestic MCI with abnormal CSF Aβ~1--42~ levels and 30 HC subjects with normal CSF Aβ~1--42~ levels. The inclusion criteria were 1) diagnosis of "MCI of the AD type" ([@bb0005]) or "prodromal AD" ([@bb0070]) as recently proposed by the National Institute on Aging and Alzheimer\'s Association workgroup ([@bb0005; @bb0100]), *i.e.* amnestic MCI subjects with abnormal CSF Aβ~1--42~ levels (\< 192 pg/ml, henceforth called MCI (Aβ +)). HC subjects were included if they had CSF Aβ~1--42~ levels \> 192 pg/ml, henceforth called HC (Aβ −) ([@bb0155]). Due to sample size restriction, the sample of 30 HC (Aβ −) subjects in the training sample included also 15 HC subjects that were part of the 54 HC subjects (test sample) in whom the prediction of subsequent conversion to MCI or AD was tested. Statistical analysis ensured that the overlap between both data sets did not bias the results (see [Statistics](#s0055){ref-type="sec"} section below).

2.2. The ADNI study {#s0030}
-------------------

ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a \$60 million, 5-year public--private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer\'s disease (AD). The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research --- approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people with early AD to be followed for 2 years.

2.3. MRI and FDG-PET acquisition {#s0035}
--------------------------------

All MRI data were acquired on 1.5 T MRI scanners using volumetric T1-weighted sequences to map brain structures, optimized for the different scanners as indicated at <http://www.loni.ucla.edu/ADNI/Research/Cores/index> ([@bb0085]).

FDG-PET scans were acquired on multiple scanners of varying resolution. FDG scans were collected as 6 × 5-min frames beginning 30 min after injection of approximately 5 mCi of tracer (details at: <http://adni.loni.ucla.edu/wp-content/uploads/2010/09/PET-Tech_Procedures_Manual_v9.5.pdf>). Prior to download, FDG-PET images had been preprocessed at the University of Berkeley according to a standard ADNI procedure (frames were co-registered, averaged, oriented along the anterior--posterior commission line and resliced to a 1.5 mm isotopic voxel space). The ADNI preprocessing protocol can be found at: <http://adni.loni.ucla.edu/methods/pet-analysis/pre-processing/>. In order to reduce the multicenter variability of the FDG-PET images, correction factors for image reconstruction were obtained on the basis of scanning a 3D Hoffman phantom object at all participating ADNI sites. This allowed to derive scanner-specific correction factors. Image reconstruction was done centrally at the ADNI PET imaging core laboratory (for details see ([@bb0095])).

2.4. Spatial normalization of MRI and FDG-PET scans {#s0040}
---------------------------------------------------

The T1 MRI scans were segmented and the resulting GM partitions were spatially normalized using high-dimensional large-deformation diffeomorphic registration as implemented in the DARTEL tool of SPM8 (<http://www.fil.ion.ucl.ac.uk/spm/software/)> ([@bb0010]). In the first step, the MRI scans were segmented into GM, white matter, and CSF partitions ([@bb0015]). Rigid body transformation was applied in order to bring GM segments into approximate alignment. The estimation of the non-linear spatial normalization parameters was calculated in iterative steps of the template generation. Within each of 6 successive cycles, an average of the GM tissue class images was generated and all GM maps were spatially normalized using a linear set of basis functions, where the optimization of the parameter estimates followed the Levenberg--Marquardt (LM) algorithm as the minimum energy optimization procedure ([@bb0010]). The normalization parameters were applied to the GM images. In the next cycle, the GM images that had been normalized during the first step were averaged and once more subjected to the spatial normalization procedure. This cycle was iterated 6 times, successively relaxing the regularization parameters as the image registration improves and the spatial resolution of the template became crisper (see also manual of SPM 8 at <http://www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf>). In the final step, the custom GM template was registered onto the ICBM GM template in MNI space included in the SPM8 package and combined with the non-linear flow fields estimated during the diffeomorphic normalization procedure described above. GM segments were modulated (*i.e.* multiplied by the Jacobian determinants of the spatial transformation) in order to yield a GM concentration in proportion to the dilation or contraction a voxel underwent during spatial normalization. The total intracranial volume (ICV) was estimated as the sum of the GM, WM and CSF tissue class images in native space obtained during the spatial normalization procedure (described above). For FDG-PET, each FDG-PET scan was coregistered to the individual\'s corresponding GM segment in native space. The spatial normalization parameters that had been estimated on the basis of the MRI images *via* DARTEL were subsequently applied to the coregistered FDG-PET images so that both the GM maps and the FDG-PET images were in MNI space.

For intensity normalization of the FDG-PET scans to the pons, a mask was manually drawn onto the GM template in MNI space, using a 3-D display in the program MIPAV (<http://mipav.cit.nih.gov/>). The binarized mask was multiplied with each spatially normalized FDG-PET image to calculate the average FDG-PET within the pons region. Each voxel of a subject\'s FDG-PET image was subsequently divided by the individual average FDG-PET value of the pons.

Correction for partial volume effects (PVEs) was done using the geometric transfer matrix (GTM) method ([@bb0140]) as implemented in the software program PMOD (PMOD Technologies Ltd, Zurich, Switzerland). Briefly, the spill-over effects between the different brain compartments are estimated by convolving binarized voxels of interest (GM *vs.* background) with the point spread function to derive the weights of the spill-over effects. Based on these weights, the PVE corrected FDG-PET images were estimated (<http://www.pmod.com/technologies/pdf/doc/PNEURO.pdf>).

All GM and FDG-PET images were finally spatially smoothed with a Gaussian kernel at 8 mm FWHM.

2.5. Construction of FDG-PET and GM ROIs {#s0045}
----------------------------------------

Voxel-based ANCOVAs were used to compare group differences between HC (Aβ −) and MCI (Aβ +) subjects (training sample), using *group* as the independent variable, and in the case of GM maps, ICV as an additional covariate. Potentially confounding variables including age, gender, and education did not differ between the HC (Aβ −) and MCI (Aβ +) groups (Supplementary Table 1), and were therefore not included as covariates in the voxel based regression analyses. The MMSE score was lower (t = − 4.9, df = 106, p \< 0.001) and ApoE ε4 genotype was more frequent in the MCI (Aβ +) compared to the HC (Aβ −) groups (χ^2^ = 23.3, df = 1, p \< 0.001). In addition to CSF Aβ~1--42~ (group selection variable), CSF total tau (Welch two-sample t-test: t = − 5.9, df = 105, p \< 0.001) and CSF p-tau~181~ (Welch two-sample t-test: t = − 7.6, df = 96, p \< 0.001) differed between groups (see also Supplementary Table 1).

For voxel-based comparison of the FDG-PET and GM maps, the statistical parametric maps of the t-scores were thresholded at the voxel-level at p = 0.001 (uncorrected), with the cluster extent threshold set to the number of expected voxel per cluster (k), including k = 624 (for FDG-PET) and k = 254 (for GM maps).

Results showed significantly lower FDG-PET metabolism primarily within the medial temporal and medial--parietal brain regions in MCI (Aβ +) compared to HC (Aβ −) (Supplementary Table 2, Supplementary [Fig. 1](#f0005){ref-type="fig"}A). For GM differences, voxels with significantly reduced GM volume (MCI (Aβ +) \< HC (Aβ −)) clustered within the inferior and medial temporal lobe (Supplementary Table 3, Supplementary Fig. 1B). No brain region showed significantly larger FDG-PET metabolism or GM volume in MCI (Aβ +) compared to HC (Aβ −). Clusters of significant group differences of FDG-PET or GM volume were binarized to create a single ROI mask for each modality. FDG-PET and GM volume within the ROI masks were subsequently obtained from the baseline FDG-PET and GM maps of each of the 54 HC subjects.

2.6. Neuropsychological tests {#s0050}
-----------------------------

Episodic memory was assessed by the Rey Auditory Verbal Learning Test (RAVLT), which includes a list of 15 words to be recalled immediately after each of the 5 verbal presentations and after a 30-min delay ([@bb0135]). A test of frontal lobe functions included the trail making test B (TMT-B, score: total number of seconds to complete the test) ([@bb0130]).

2.7. Statistics {#s0055}
---------------

"Conversion" was defined as a change in diagnosis from HC to MCI or AD dementia during the follow-up in the 54 HC subjects (test set). Logistic regression analyses were used to predict conversion status (non-converter *vs.* converters). The predictors included baseline FDG-PET ROI (both uncorrected or corrected for PVE), GM volume ROI, RAVLT immediate free recall, RAVLT delayed free recall, and the TMT-B test. Separate logistic regression models were constructed for each predictor and significant predictors were subsequently combined in a final model to test additive effects. Each model was corrected for age, gender, and ApoE genotype (ε4 allele carriers *vs.* ε4 allele non-carriers). Normal distribution of each predictor was tested by Shapiro--Wilks tests, and --- in case of non-normal distribution --- the variables were rank transformed. All predictors were transformed into z-scores before entering them into the logistic regression model to yield better comparison of the regression weights between predictors. ROC analyses for significant predictors were conducted, using bootstrapping with n = 1000 resampling iterations to estimate the area under the curve (AUC) and the specificity at a fixed sensitivity of 80%. The bootstrapped 95% confidence intervals (95% CI) of the AUC and specificity are reported. In order to examine the robustness of the results, the logistic regression analyses for the prediction of conversion in the 54 HC subjects were repeated, now excluding those 15 HC subjects who had also been part of the training sample for the establishment of the ROIs (see above "Construction of FDG-PET and GM ROIs"). All of these analyses were done with the program R (version 2.12.1, [www.r-project.org](http://www.r-project.org){#ir0135}).

Voxel-based comparisons of FDG-PET and GM maps between HC converters vs. non-converters were conducted through ANCOVAs, controlled for age (that differed significantly between converters and non-converters). For the voxel-based group comparison of GM volume, the ICV was an additional covariate in the regression analyses. The statistical parametric maps were thresholded at p = 0.001 (uncorrected at voxel level), where only clusters exceeding the expected number of voxels per cluster (cluster extent threshold) were reported. Voxel-wise maps of the effect size *d* ([@bb0035]) were computed to display group differences unbiased by sample size.

3. Results {#s0010}
==========

3.1. Conversion from HC to MCI or AD dementia {#s0060}
---------------------------------------------

The descriptive statistics of the HC converters and HC non-converters are displayed in [Table 1](#t0005){ref-type="table"}. Over a time interval of 54 months, 11 out of 54 HC subjects progressed to MCI or AD (MCI: n = 9, AD dementia: n = 2). All of the 11 subjects had converted after 3 years, except for one subject (time to conversion = 4 years). For the non-converters, all of the subjects had been assessed at least for 3 years of clinical follow-up duration. Nineteen out of 43 non-converters (44%) had also been assessed after at least 4 years. HC converters were significantly older than HC non-converters (t = − 3.5, df = 16.6, p = 0.002).

3.2. Prediction of conversion from HC to MCI or AD dementia {#s0065}
-----------------------------------------------------------

Logistic regression analyses showed that the FDG-PET ROI (including medial temporal and parietal brain regions) was a significant predictor of HC conversion (B = − 1.4 z-core units, SE = .5, p = 0.006), independent of age, gender, and ApoE ε4 status. The results of the ROC analysis are shown in [Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}. Specifically, the ROC analysis for the age-adjusted FDG-PET ROI yielded an AUC of 77.8% (95% CI = (62.2%, 93.6%)). The bootstrapped median specificity was 51.2% (95% CI = (27.9%, 93%)) at a fixed sensitivity of 80%. The FDG-PET ROI after PVE correction remained a significant predictor of conversion (B = 1.4 z-score units, SE = .5, p = 0.004), with the AUC remaining virtually the same when compared to the FDG-PET model without PVE correction: AUC = 80.3% (95% CI = (66.2%, 94.5%)).

The ROI of GM volume (medial temporal lobe regions) was not a significant predictor of conversion (p = 0.07). Because the significance threshold was missed by a small margin, the ROC analysis was computed nevertheless. At a sensitivity of 80%, the mean specificity of the GM volume ROI was below 50%.

For neuropsychological tests, the logistic regression analyses showed that TMT-B test scores discriminated HC converters from HC non-converters (B = 0.88 z-score units, SE = 0.4, p = 0.03), adjusted for age, gender, and ApoE ε4 genotype. The tests of free recall were not significant predictors. ROC analysis showed for age-adjusted TMT-B scores an AUC of 71% (95% CI = 50.4%, 91.7%). At a fixed sensitivity of 80%, the median specificity was 34.9% (95% CI = 9.3%, 95.3%). In a combined model, TMT-B test scores significantly added to the predictive accuracy of the FDG-PET ROI (TMT-B: B = 1.8 z-score units, SE = 0.7, p = 0.01, FDG-PET ROI: B = − 2.3 z-score units, SE = 0.8, p = 0.005). The AUC of the combined model of FDG-PET plus TMT-B increased to 89.4% (95% CI = 79.9%, 98.9%). The sensitivity was 81.8% and the specificity was 79.1% for the combined model.

When repeating the regression analyses excluding those 15 HC subjects who had been also part of the training sample, the result pattern remained the same for all analyses (data not shown), indicating that the results were not influenced by the partial overlap between training and test samples.

CSF biomarker measurements were available in a subset of the 54 HC subjects including 7 HC converters and 22 HC non-converters. Abnormal CSF Aβ~1--42~ levels (\< 192 pg/ml) ([@bb0155]) were present in 5 (71%) HC converters and 9 (41%) HC non-converters. Abnormal CSF p-tau~181~ levels (\> 23 pg/ml) ([@bb0155]) were present in 3 (75%) HC converters and 6 (27%) of HC non-converters.

3.3. Voxel based comparison of FDG-PET and MRI between HC converters and HC stable {#s0070}
----------------------------------------------------------------------------------

In the voxel-based comparison of FDG-PET, HC converters showed hypometabolism within the areas of the medial frontal gyrus and the temporo-parietal brain areas ([Fig. 3](#f0015){ref-type="fig"}, for cluster coordinates see Supplementary Table 4). No brain areas showed increased FDG-PET in HC converters when compared to HC stable subjects. The comparison of GM volume between HC converters and HC non-converters produced no significant clusters of group differences.

Lastly, we mapped the effect size *d* of FDG-PET and GM volume for the comparison between HC converters and HC non-converters without thresholding the maps on the basis of p-values. Visual inspection of the effect size maps shows that the effect sizes of group differences (*i.e.* lower FDG-PET in HC converters) are highest within the temporal, frontal, and parietal brain areas ([Fig. 4](#f0020){ref-type="fig"}A), and are higher in most brain areas when compared to the group difference in GM volume ([Fig. 4](#f0020){ref-type="fig"}B). For GM volume, the highest effect sizes of decreased GM volume within the HC converters group are primarily centered within the medial temporal lobe.

4. Discussion {#s0015}
=============

Our findings of the prediction of the conversion from HC to MCI and AD dementia based on the *a priori* determined FDG-PET ROI (located in the medial temporal and parietal lobes) is consistent with previous studies showing that medial temporal and parietal FDG-PET was associated with faster cognitive decline ([@bb0090]) and hippocampal/entorhinal FDG-PET was sensitive to preclinical AD ([@bb0045; @bb0110]). These regions of reduced FDG-PET in medial temporal and medial parietal brain areas can be considered a subset of those temporo-parietal areas (*i.e.* medial and lateral parietal lobes & medial temporal lobes) that are typically affected in AD dementia ([@bb0105]). Whereas we found a predictive effect of the FDG-PET ROI on subsequent clinical progression, we did not detect a significant predictive value of the medial temporal GM volume ROI. The findings are in line with MRI studies reporting that baseline total GM or medial temporal GM in HC subjects did not predict global cognitive decline ([@bb0090]) or progression to MCI or AD ([@bb0145]). However, the results are in disagreement with other studies suggesting that medial temporal GM volume is affected in preclinical AD ([@bb0030; @bb0065]). In particular, recent studies showed that a summary measure of cortical thickness ROIs including several temporal, parietal and prefrontal brain regions showed predictive value for the classification of subjects who subsequently converted to AD dementia ([@bb0060]). Inconsistencies between the current and previous findings might be explained by methodological differences including differences in cortical thickness *vs.* morphometric measures ([@bb0080; @bb0175]), or a more advanced state of disease severity of HC subjects included in those studies which detected gray matter atrophy at the preclinical stage ([@bb0060]). The most parsimonious explanation is, however, that the subtle gray matter differences were already present but remained below the significance threshold in the current study. The examination of the effect size maps of gray matter volume differences confirmed that reductions in gray matter volume were mostly confined to the medial temporal lobe, which is in general agreement with previous reports of voxel-based analysis showing that GM volume decreases exclusively within the medial temporal and angular gyrus in HC subjects who later convert to MCI ([@bb0160]). Importantly, the effect size map confirmed that FDG-PET hypometabolism was widely spread out within the gray matter brain areas, supporting the notion that FDG-PET was more affected compared to GM volume in subjects who showed clinical worsening that may correspond to preclinical AD.

For neuropsychological tests, the TMT-B test but not measures of episodic memory were predictive of clinical progression. We previously reported that the TMT-B test outperformed other neuropsychological tests including tests of free recall, category fluency, digit span, and the Boston naming test for predicting conversion from MCI to AD dementia ([@bb0075]). Together with the previous findings, the current results suggest that TMT-B test might reflect cognitive function that is affected early in the course of AD. The TMT-B test is thought to be a measure of visual attention and cognitive flexibility associated with frontal and parietal lobe function ([@bb0180]). It is not known exactly which functional and structural brain changes in AD underlie the cognitive performance changes on the TMT-B test early in the course of AD. However, from a clinical point of view, the combination of the TMT-B and regional FDG-PET provides high sensitivity and specificity for the detection of clinical worsening in elderly HC subjects --- possibly at an early stage of AD dementia. It should be noted that no systematic screening of a large range of neuropsychological tests or biomarkers candidates was done in the current study. Thus, neuropsychological tests or biomarkers other than those tested here may be relevant as well ([@bb0025; @bb0040; @bb0165; @bb0170]). In the current study, some of the *a priori* selected predictors that were previously shown to be sensitive to prodromal AD ([@bb0075]) were confirmed to be successful for the prediction of clinical progression in HC subjects. It is for larger future studies to validate the current results and define a potentially extended test set of best predictors of preclinical AD. Apart from the current objective measures of neuropsychological ability, subjective memory complaints have previously been shown to be a potential predictor of subsequent memory decline ([@bb0020; @bb0150]) in elderly cognitively normal subjects and may be tested in future studies as well.

For the interpretation of the current results, it is important to note that not all HC subjects who converted to MCI may eventually progress to AD dementia. Compared to the HC non-converters, a higher proportion of HC converters showed abnormal measures on primary AD pathology as measured by CSF Aβ and p-tau~181~ levels that were available in a subset of the patients, supporting the notion that the HC converters were afflicted by preclinical AD. The development to AD dementia need to be confirmed, however, in future follow-ups within the ADNI project. It should also be noted that the subset of 54 HC subjects represents a subsample of the overall total of 229 HC subjects assessed in ADNI I. The sample size reduction was majorly due to the ADNI I study design, where a subset of the 229 HC subjects received FDG-PET at baseline. For the current study further requirements included follow-up duration (\> 3 years) and a CDR of 0 for the HC non-converters. We considered these requirements useful in order to be able to clearly define a control group to establish a sensitive prediction model of preclinical AD.

Increased brain Aβ PET binding in the brain has previously been shown to be predictive for the conversion to AD dementia in MCI subjects and may also predict clinical progression at the preclinical stage of AD ([@bb0115; @bb0120]). Thus the question needs to be addressed to what extent the current markers add to measures of primary pathology (tau or Aβ) to the detection of preclinical AD ([@bb0055; @bb0125]).

Appendix A. Supplementary data {#s0075}
==============================

Supplementary material.
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![Projection of voxel-based t-statistic map onto axial brain slices. Yellow designates t-values for significantly higher FDG-PET in HC non-converters compared to HC converters. The opposite contrast (HC converters \> HC stable) was not significant.](gr3){#f0015}

![Maps of effect size *d* for the group comparison of HC converter *vs.* HC non-converter are superimposed onto axial brain slices for FDG-PET (A) and MRI gray matter (B). Red colors indicate a positive effect size, *i.e.* HC non-converter \> HC converter, the bluish colors indicate the opposite effect. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr4){#f0020}

###### 

Demographic, clinical and biomarker statistics in HC converters and HC non-converters. The mean and standard deviation (SD) are indicated where appropriate.

  Group              N    Age (yrs)    Sex (f/m)   Edu (yrs)    ApoE ε4 (+/−)   MMSE         TMT-B (in sec.)   Recall immed.   Recall del.
  ------------------ ---- ------------ ----------- ------------ --------------- ------------ ----------------- --------------- -------------
  HC converter       11   78.9 (3.7)   5/6         16.3 (2.9)   4/7             29.0 (0.8)   141.2 (45.1)      40 (10.4)       5.6 (4.4)
  HC non-converter   43   74.3 (4.6)   15/28       16.6 (3.0)   12/31           28.4 (1.2)   111.2 (32.3)      44.1 (10.1)     7.7 (4.1)

ApoE (+) = ApoE ε4 carriers, ApoE (−) = ApoE ε4 non-carriers, Edu = education, Recall immed. = immediate free recall, Recall del. = delayed free recall, yrs = years, f = female, m = male, sec. = seconds.

###### 

Specificity at a fixed sensitivity of 80% and AUC for the classification of HC converter *vs.* HC non-converter.

  Predictor                                \% AUC (95% CI)     \% specificity (at 80% sensitivity)
  ---------------------------------------- ------------------- ---------------------------------------
  FDG-PET ROI                              77.8 (62.2, 93.6)   51.2
  PVE corrected FDG-PET ROI                80.3 (66.2, 94.5)   67.4
  TMT-B                                    71 (50.4, 91.7)     34.9
  Combined FDG-PET & TMT-B                 89.4 (79.9, 98.9)   79.1[a](#tf0005){ref-type="table-fn"}
  Combined PVE corrected FDG-PET & TMT-B   92 (84.2, 99.8)     80.7[a](#tf0005){ref-type="table-fn"}

Exact sensitivity was 81.8%.
